MX357293B - Anticuerpos anti-cd26 y usos de los mismos. - Google Patents

Anticuerpos anti-cd26 y usos de los mismos.

Info

Publication number
MX357293B
MX357293B MX2014014935A MX2014014935A MX357293B MX 357293 B MX357293 B MX 357293B MX 2014014935 A MX2014014935 A MX 2014014935A MX 2014014935 A MX2014014935 A MX 2014014935A MX 357293 B MX357293 B MX 357293B
Authority
MX
Mexico
Prior art keywords
present
provides
well
treating
antibodies
Prior art date
Application number
MX2014014935A
Other languages
English (en)
Other versions
MX2014014935A (es
Inventor
Francesco Di Naro Antonio
Original Assignee
Adienne S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48092884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357293(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adienne S A filed Critical Adienne S A
Publication of MX2014014935A publication Critical patent/MX2014014935A/es
Publication of MX357293B publication Critical patent/MX357293B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

La presente invención se refiere a anticuerpos novedosos capaces de unirse a CD26, así como su uso como un medicamento. Además, la presente invención proporciona anticuerpos para uso en el tratamiento y/o prevención de rechazo inverso (GvHD) para uso en el tratamiento de anemia aplásica y/o para uso en promover el injertado después de transplante de blastocitos hematopoyéticos. Además, la presente invención proporciona composiciones farmacéuticas que comprenden por lo menos un anticuerpo de la presente invención así como proporcionar un kit de partes.
MX2014014935A 2013-02-19 2014-02-19 Anticuerpos anti-cd26 y usos de los mismos. MX357293B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13425029.9A EP2767549A1 (en) 2013-02-19 2013-02-19 Anti-CD26 antibodies and uses thereof
PCT/EP2014/053243 WO2014128168A1 (en) 2013-02-19 2014-02-19 Anti-cd26 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2014014935A MX2014014935A (es) 2015-06-17
MX357293B true MX357293B (es) 2018-07-04

Family

ID=48092884

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014935A MX357293B (es) 2013-02-19 2014-02-19 Anticuerpos anti-cd26 y usos de los mismos.

Country Status (26)

Country Link
US (2) US9376498B2 (es)
EP (3) EP2767549A1 (es)
JP (2) JP6240195B2 (es)
KR (1) KR101869589B1 (es)
CN (1) CN104684931B (es)
AU (1) AU2014220777B2 (es)
CA (1) CA2874422C (es)
CY (1) CY1121980T1 (es)
DK (1) DK2864359T3 (es)
ES (1) ES2738283T3 (es)
HK (1) HK1205151A1 (es)
HR (1) HRP20191277T8 (es)
HU (1) HUE045150T2 (es)
IL (1) IL237244B (es)
LT (1) LT2864359T (es)
ME (1) ME03753B (es)
MX (1) MX357293B (es)
NZ (1) NZ631111A (es)
PL (1) PL2864359T3 (es)
PT (1) PT2864359T (es)
RS (1) RS59093B1 (es)
RU (1) RU2662933C2 (es)
SA (1) SA515360248B1 (es)
SI (1) SI2864359T1 (es)
TR (1) TR201910572T4 (es)
WO (1) WO2014128168A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11242399B2 (en) * 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
US10630229B2 (en) * 2016-10-11 2020-04-21 Kevin Stapleton Panel mounting bracket with grounding mid-clamp and related methods
KR101960414B1 (ko) * 2016-11-11 2019-03-27 대한민국 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도
KR20200103003A (ko) 2017-12-22 2020-09-01 아디에네 에스.에이. 항-cd26 리간드의 생물학적 활성을 결정하기 위한 정량적인 세포적 방법
CN109709337B (zh) * 2018-12-28 2021-09-14 江苏众红生物工程创药研究院有限公司 人cd26的免疫组化检测试剂盒及其临床应用
EP4188953A1 (en) * 2020-07-28 2023-06-07 Adienne S.A. Treatment of idiopathic inflammatory myopathies
CA3218127A1 (en) * 2021-05-13 2022-11-17 Adienne S.A. Methods of treating graft versus host disease
CA3218123A1 (en) * 2021-05-13 2022-11-17 Antonio Francesco Di Naro Methods of treating dermatomyositis
CN118359716A (zh) * 2023-01-18 2024-07-19 江苏众红生物工程创药研究院有限公司 抗cd26抗体及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NL9400309A (nl) * 1993-11-04 1995-06-01 Eurogenetics Nv Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
ATE335005T1 (de) 1998-04-15 2006-08-15 Genentech Inc Menschliches protein mit in vitro antiproliferativer aktivität.
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
EP1392361A4 (en) * 2001-05-11 2009-08-05 Univ Texas THERAPY BASED ON ANTI-CD26 MONOCLONAL ANTIBODIES AGAINST DISORDERS ASSOCIATED WITH CELLS EXPRESSING CD26
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
AU2006272713A1 (en) 2005-07-22 2007-02-01 Y's Therapeutics Co, Ltd. Anti-CD26 antibodies and methods of use thereof
BRPI0616077B8 (pt) * 2005-09-14 2021-05-25 Takeda Pharmaceuticals Co composição farmacêutica formulada em uma dose única, kit, artigo de manufatura, uso da composição farmacêutica e uso de um ou mais compostos antidiabéticos
US8846393B2 (en) * 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
RU2331881C1 (ru) * 2007-03-09 2008-08-20 ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ определения риска развития атопических заболеваний у новорожденных детей
BRPI0919473A2 (pt) 2008-09-26 2017-08-29 Oncomed Pharm Inc Agentes de ligação frizzled e usos dos mesmos
EP2605765B1 (en) * 2010-08-18 2019-05-08 Theresa Deisher Dexamethasone for use in treating osteoarthritis, liver failure, type-2 diabetes mellitus, stroke and parkinson's disease, in combination with stem cell treatment
EP2767549A1 (en) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof

Also Published As

Publication number Publication date
US20160264676A1 (en) 2016-09-15
HK1205151A1 (en) 2015-12-11
AU2014220777A1 (en) 2014-11-27
WO2014128168A1 (en) 2014-08-28
LT2864359T (lt) 2019-09-25
EP2864359B1 (en) 2019-04-24
AU2014220777B2 (en) 2017-03-16
CN104684931B (zh) 2019-08-27
ME03753B (me) 2021-04-20
EP2767549A1 (en) 2014-08-20
MX2014014935A (es) 2015-06-17
PL2864359T3 (pl) 2019-11-29
RS59093B1 (sr) 2019-09-30
HRP20191277T8 (hr) 2019-11-01
TR201910572T4 (tr) 2019-08-21
JP2015529204A (ja) 2015-10-05
IL237244A0 (en) 2015-04-30
SA515360248B1 (ar) 2017-02-20
IL237244B (en) 2019-09-26
RU2662933C2 (ru) 2018-07-31
SI2864359T1 (sl) 2019-09-30
RU2014153440A (ru) 2016-07-20
US9376498B2 (en) 2016-06-28
KR20150023419A (ko) 2015-03-05
PT2864359T (pt) 2019-07-26
JP2017221205A (ja) 2017-12-21
BR112015002130A2 (pt) 2017-11-07
JP6240195B2 (ja) 2017-11-29
ES2738283T3 (es) 2020-01-21
HRP20191277T1 (hr) 2019-10-18
CA2874422A1 (en) 2014-08-28
EP2864359A1 (en) 2015-04-29
CY1121980T1 (el) 2020-10-14
US20150017178A1 (en) 2015-01-15
EP3536711A1 (en) 2019-09-11
NZ631111A (en) 2017-06-30
DK2864359T3 (da) 2019-07-22
CN104684931A (zh) 2015-06-03
US10208126B2 (en) 2019-02-19
CA2874422C (en) 2021-10-19
KR101869589B1 (ko) 2018-06-20
HUE045150T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
MX357293B (es) Anticuerpos anti-cd26 y usos de los mismos.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
EA201400579A1 (ru) Антитела к il-36r
PH12015500196A1 (en) Methods of treating a tauopathy
PH12017500864A1 (en) Anti-notch1 antibodies
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
PH12014502406A1 (en) Anti-il-23p19 antibodies
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
EA201201357A1 (ru) Антитела к cd40
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
MX2016004556A (es) Composicion de hueso comprimido y metodo para usar la misma.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2019015604A (es) Anticuerpos anti-tau y usos de los mismos en el tratamiento de una tauopatia.
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
PH12014501176A1 (en) Anticoagulant reversal agents
NZ631639A (en) Methods and compositions for treating and diagnosing acute myocardial infarction
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions
TN2014000207A1 (en) Anti il-36r antibodies

Legal Events

Date Code Title Description
FG Grant or registration